174 related articles for article (PubMed ID: 34936091)
1. Virus filtration: A review of current and future practices in bioprocessing.
Johnson SA; Chen S; Bolton G; Chen Q; Lute S; Fisher J; Brorson K
Biotechnol Bioeng; 2022 Mar; 119(3):743-761. PubMed ID: 34936091
[TBL] [Abstract][Full Text] [Related]
2. Use of MMV as a Single Worst-Case Model Virus in Viral Filter Validation Studies.
Gefroh E; Dehghani H; McClure M; Connell-Crowley L; Vedantham G
PDA J Pharm Sci Technol; 2014; 68(3):297-311. PubMed ID: 25188350
[TBL] [Abstract][Full Text] [Related]
3. Proceedings of the 2019 Viral Clearance Symposium, Session 6: Virus-Retentive Filtration.
O'Donnell S; Bolton G
PDA J Pharm Sci Technol; 2022; 76(4):349-357. PubMed ID: 34911825
[TBL] [Abstract][Full Text] [Related]
4. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
[TBL] [Abstract][Full Text] [Related]
5. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
Ma J; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
[TBL] [Abstract][Full Text] [Related]
6. Meeting report--workshop on virus removal by filtration: trends and new developments.
Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Kreil TR; Robertson JS; Ruffing M; Ruiz S
PDA J Pharm Sci Technol; 2013; 67(2):98-104. PubMed ID: 23569071
[TBL] [Abstract][Full Text] [Related]
7. Performance of a novel Viresolve NFR virus filter.
Brough H; Antoniou C; Carter J; Jakubik J; Xu Y; Lutz H
Biotechnol Prog; 2002; 18(4):782-95. PubMed ID: 12153313
[TBL] [Abstract][Full Text] [Related]
8. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
9. Protection of biomanufacturing processes from virus contamination through upstream virus filtration of cell culture media.
Wieser A; Modrof J; Kreil TR
Biotechnol Bioeng; 2023 Oct; 120(10):2917-2924. PubMed ID: 37337932
[TBL] [Abstract][Full Text] [Related]
10. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
[TBL] [Abstract][Full Text] [Related]
11. Proceedings of the 2019 Viral Clearance Symposium, Session 7: Cell Banks and U.S. Pharmacopeia.
O'Donnell S
PDA J Pharm Sci Technol; 2022; 76(4):358-361. PubMed ID: 34911823
[TBL] [Abstract][Full Text] [Related]
12. Development of a transient inline spiking system for evaluating virus clearance in continuous bioprocessing-Proof of concept for virus filtration.
Malakian A; Jung SY; Afzal MA; Carbrello C; Giglia S; Johnson M; Miller C; Rayfield W; Boenitz D; Cetlin D; Zydney AL
Biotechnol Bioeng; 2022 Aug; 119(8):2134-2141. PubMed ID: 35470427
[TBL] [Abstract][Full Text] [Related]
13. Suitability of a generic virus safety evaluation for monoclonal antibody investigational new drug applications.
Sipple P; Nguyen T; Patel K; Jaffe N; Chen Y; Khetan A
Biotechnol Prog; 2019 Sep; 35(5):e2850. PubMed ID: 31125511
[TBL] [Abstract][Full Text] [Related]
14. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
Kreil TR; Roush D
PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
[TBL] [Abstract][Full Text] [Related]
15. Safety assurance for biologics manufactured in mammalian cell cultures: a multitiered strategy.
Chen D
Adv Biochem Eng Biotechnol; 2014; 139():167-83. PubMed ID: 23719711
[TBL] [Abstract][Full Text] [Related]
16. Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices.
Rosenberg AS; Cherney B; Brorson K; Clouse K; Kozlowski S; Hughes P; Friedman R
PDA J Pharm Sci Technol; 2011; 65(6):563-7. PubMed ID: 22294578
[TBL] [Abstract][Full Text] [Related]
17. Impact of virus preparation quality on parvovirus filter performance.
Slocum A; Burnham M; Genest P; Venkiteshwaran A; Chen D; Hughes J
Biotechnol Bioeng; 2013 Jan; 110(1):229-39. PubMed ID: 22766979
[TBL] [Abstract][Full Text] [Related]
18. Integrated viral clearance strategies-reflecting on the present, projecting to the future.
Roush DJ
Curr Opin Biotechnol; 2018 Oct; 53():137-143. PubMed ID: 29367164
[TBL] [Abstract][Full Text] [Related]
19. Process scale considerations in evaluation studies and scale-up.
Walter JK; Werz W; Berthold W
Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
[TBL] [Abstract][Full Text] [Related]
20. Proceedings of the 2017 Viral Clearance Symposium, Session 1.2: Upstream Mitigation, Part 2-Virus Barrier Filter and HTST.
Chen D; Bolton G
PDA J Pharm Sci Technol; 2018; 72(5):462-469. PubMed ID: 30030355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
